Practices

Mergers and Acquisitions

In Depth

Since 2021, Cooley has handled 1,600+ M&A transactions with an aggregate value of $750 billion+, making our practice one of the most active in the world. We represent

all categories of participants in transactions, including buyers, sellers, major stockholders, lenders, financial advisors, management, special board committees, venture capitalists, individual investors, private equity funds, hedge funds and others.

Recent M&A experience

Public company buy-side deals

  • Alumis’ (Nasdaq: ALMS) acquisition of ACELYRIN (Nasdaq: SLRN) in an all-stock transaction
  • BioMarin Pharmaceutical’s (Nasdaq: BMRN) acquisition of Inozyme Pharma (Nasdaq: INZY) for approximately $270 million
  • Eagle Pharmaceutical’s (Nasdaq: EGRX) acquisition of Acacia Pharma (LTS: 0PNT) for $104 million
  • Horizon Therapeutics’ (Nasdaq: HZNP) acquisition of Viela Bio (Nasdaq: VIE) for $3.1 billion
  • Mannkind’s (Nasdaq: MNKD) acquisition of scPharmaceuticals (Nasdaq: SCPH)
  • Sunrun’s (Nasdaq: RUN) acquisition of Vivint Solar (NYSE: VSLR) in a stock deal valued at $3.2 billion
  • TiVo’s (Nasdaq: TIVO) combination with Xperi (Nasdaq: XPER) for approximately $1.5 billion
  • Zoom’s (Nasdaq: ZM) agreement to acquire Five9 (Nasdaq: FIVN) for $14.7 billion

Public company sell-side deals

  • Accolade’s (Nasdaq: ACCD) sale to Transcarent for $621 million
  • Chimerix’s (Nasdaq: CMRX) sale to Jazz Pharmaceuticals (Nasdaq: JAZZ) for $935 million
  • Cidara Therapeutics’ (Nasdaq: CDTX) sale to Merck (NYSE: MRK) for approximately $9.2 billion
  • Confluent’s (Nasdaq: CFLT) sale to IBM (NYSE: IBM) for approximately $11 billion
  • Dynavax’s (Nasdaq: DVAX) sale to Sanofi (PAR: SAN) for approximately $2.2 billion
  • Horizon Therapeutics’ (Nasdaq: HZNP) sale to Amgen (Nasdaq: AMGN) for $28.3 billion
  • IAA’s (NYSE: IAA) sale to Ritchie Bros. (NYSE: RBA) in a $7.3 billion stock and cash transaction, IAA’s related cooperation agreement with Ancora Advisors,  and Ritchie Bros.’ concurrent $500 million investment from Starboard Value
  • PetIQ’s (Nasdaq: PETQ) sale to Bansk Group for $1.5 billion
  • RAPT Therapeutics’ (Nasdaq: RAPT) sale to GSK (LON: GSK) for up to $2.2 billion
  • RayzeBio’s (Nasdaq: RYZB) sale to Bristol Myers Squibb (NYSE: BMY) for approximately $4.1 billion

Private company buy-side deals

  • Cedar Cares’ acquisition of OODA Health for $425 million
  • Dropbox’s (Nasdaq: DBX) acquisitions of Reclaim, Promoted, FormSwift and DocSend
  • Fastly’s (Nasdaq: FSLY) acquisition of Signal Sciences for approximately $775 million, Glitch and Domainr
  • Lantheus Medical Imaging’s (Nasdaq:LNTH) acquisition of Evergreen Theragnostics for up to $1 billion
  • LegalZoom’s (Nasdaq: LZ) acquisitions of Dratavolo, Neeva, TruEra and LeapYear Technologies
  • Mirum Pharmaceuticals’ (Nasdaq: MIRM) acquisition of Bluejay Therapeutics for up to $820 million
  • Netflix’s (Nasdaq: NFLX) acquisitions of Boss Fight Entertainment, Ready Player Me and Spry Fox
  • Uber’s (NYSE: UBER) acquisitions of Drizly for $1.1 billion, Transplace for $2.25 billion and Mighty AI
  • Zoom’s (Nasdaq: ZM) acquisitions of Workvivo, Solvvy, Keybase, BrightHire and Bonsai

Private company sell-side deals

  • Capstan Therapeutics’ sale to AbbVie (NYSE: ABBV) for $2.1 billion
  • Column Tax’s sale to Aiwyn
  • H. Irving and Susanne B. Grousbeck’s sale of the Boston Celtics to an investor group led by William Chisholm for $6.1 billion
  • io Product’s sale to OpenAI for $6.5 billion
  • Nativo’s sale to Life360 (Nasdaq: LIF) for $120 million
  • PrizePicks’ sale to Allwyn for up to $4.15 billion
  • Qualified.com’s agreement to merge with Salesforce (NYSE: CRM) 
  • SciTec’s sale to Firefly Aerospace (Nasdaq: FLY) for $855 million
  • SiteOne Therapeutics’ sale to Eli Lilly (NYSE: LLY) for approximately $1 billion
  • Stash Financial’s agreement to be acquired by Grab Holdings (Nasdaq: GRAB) for approximately $425 million
  • The Clearing Company’s agreement to sell to Coinbase (Nasdaq: COIN)
  • Touchland’s sale to Church & Dwight (NYSE: CHD) for up to $880 million

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.